Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Vertex Cystic Fibrosis Drug Gets Green Light
by Lisa M. Jarvis
February 6, 2012
| A version of this story appeared in
Volume 90, Issue 6
Vertex Pharmaceuticals has received FDA approval for Kalydeco, the first drug to treat the underlying cause of cystic fibrosis rather than just the symptoms. The regulatory green light came nearly three months ahead of FDA’s deadline for making a decision. Kalydeco, which increases the flow of water and salt across cell membranes, is approved to treat only the small subset of the cystic fibrosis population carrying a genetic mutation called G551D. Vertex plans to charge $294,000 annually for the pill, which is taken twice daily.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter